These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
181 related articles for article (PubMed ID: 28502100)
21. [Analysis of HER2 gene status in breast cancer with HER2 protein overexpression]. Zeng X; Liang ZY; Wu SF; Zhou WX; Gao J; Liu TH Zhonghua Bing Li Xue Za Zhi; 2006 Oct; 35(10):584-8. PubMed ID: 17134563 [TBL] [Abstract][Full Text] [Related]
22. Chromosome 17 polysomy: correlation with histological parameters and HER2NEU gene amplification. Orsaria M; Khelifa S; Buza N; Kamath A; Hui P J Clin Pathol; 2013 Dec; 66(12):1070-5. PubMed ID: 23908451 [TBL] [Abstract][Full Text] [Related]
23. Assessment of HER2 status in invasive breast cancers with increased centromere 17 copy number. Jang MH; Kim EJ; Kim HJ; Chung YR; Park SY Breast Cancer Res Treat; 2015 Aug; 153(1):67-77. PubMed ID: 26223814 [TBL] [Abstract][Full Text] [Related]
24. HER2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneity. Hanna WM; Rüschoff J; Bilous M; Coudry RA; Dowsett M; Osamura RY; Penault-Llorca F; van de Vijver M; Viale G Mod Pathol; 2014 Jan; 27(1):4-18. PubMed ID: 23807776 [TBL] [Abstract][Full Text] [Related]
25. RAI1 Alternate Probe Identifies Additional Breast Cancer Cases as Amplified Following Equivocal HER2 Fluorescence In Situ Hybridization Testing: Experience From a National Reference Laboratory. Hui L; Geiersbach KB; Downs-Kelly E; Gulbahce HE Arch Pathol Lab Med; 2017 Feb; 141(2):274-278. PubMed ID: 27959582 [TBL] [Abstract][Full Text] [Related]
26. Impact of 2013 ASCO/CAP guidelines on HER2 determination of invasive breast cancer: A single institution experience using frontline dual-color FISH. Ragazzi M; Bisagni A; Gasparini E; Kuhn E; Bassano C; Tamagnini I; Foroni M; Bortesi M; Falco G; Ferrari G; Braglia L; Savoldi L; Bologna A; Di Cicilia R; Bisagni G; Gardini G Breast; 2017 Aug; 34():65-72. PubMed ID: 28521178 [TBL] [Abstract][Full Text] [Related]
27. Fluorescence in situ hybridization of chromosome 17 polysomy in breast cancer using thin tissue sections causes the loss of CEP17 and HER2 signals. Jiang H; Bai X; Zhao T; Zhang C; Zhang X Oncol Rep; 2014 Nov; 32(5):1889-96. PubMed ID: 25119636 [TBL] [Abstract][Full Text] [Related]
28. Poor prognostic significance of unamplified chromosome 17 polysomy in invasive breast carcinoma. Krishnamurti U; Hammers JL; Atem FD; Storto PD; Silverman JF Mod Pathol; 2009 Aug; 22(8):1044-8. PubMed ID: 19396150 [TBL] [Abstract][Full Text] [Related]
29. Prognostic significance of centromere 17 copy number gain in breast cancer depends on breast cancer subtype. Lee K; Jang MH; Chung YR; Lee Y; Kang E; Kim SW; Kim YJ; Kim JH; Kim IA; Park SY Hum Pathol; 2017 Mar; 61():111-120. PubMed ID: 27989787 [TBL] [Abstract][Full Text] [Related]
30. Frequency of chromosome 17 polysomy in relation to CEP17 copy number in a large breast cancer cohort. Koudelakova V; Trojanec R; Vrbkova J; Donevska S; Bouchalova K; Kolar Z; Varanasi L; Hajduch M Genes Chromosomes Cancer; 2016 May; 55(5):409-17. PubMed ID: 26847577 [TBL] [Abstract][Full Text] [Related]
31. Prognostic significance of equivocal human epidermal growth factor receptor 2 results and clinical utility of alternative chromosome 17 genes in patients with invasive breast cancer: A cohort study. Sneige N; Hess KR; Multani AS; Gong Y; Ibrahim NK Cancer; 2017 Apr; 123(7):1115-1123. PubMed ID: 27893937 [TBL] [Abstract][Full Text] [Related]
32. Genomic Copy Number Analysis of HER2-Equivocal Breast Cancers. Geiersbach KB; Willmore-Payne C; Pasi AV; Paxton CN; Werner TL; Xu X; Wittwer CT; Gulbahce HE; Downs-Kelly E Am J Clin Pathol; 2016 Oct; 146(4):439-47. PubMed ID: 27614666 [TBL] [Abstract][Full Text] [Related]
33. Co-amplification of the HER2 gene and chromosome 17 centromere: a potential diagnostic pitfall in HER2 testing in breast cancer. Varga Z; Tubbs RR; Wang Z; Sun Y; Noske A; Kradolfer D; Bosshard G; Jochum W; Moch H; Öhlschlegel C Breast Cancer Res Treat; 2012 Apr; 132(3):925-35. PubMed ID: 21698407 [TBL] [Abstract][Full Text] [Related]
34. Role of polysomy 17 in transitional cell carcinoma of the bladder: immunohistochemical study of HER2/neu expression and fish analysis of c-erbB-2 gene and chromosome 17. Simonetti S; Russo R; Ciancia G; Altieri V; De Rosa G; Insabato L Int J Surg Pathol; 2009 Jun; 17(3):198-205. PubMed ID: 19443884 [TBL] [Abstract][Full Text] [Related]
35. Clinicopathologic features of breast cancer reclassified as HER2-amplified by fluorescence in situ hybridization with alternative chromosome 17 probes. Blanton KC; Deal AM; Kaiser-Rogers KA; Anders CK; O'Connor SM; Hertel JD; Calhoun BC Ann Diagn Pathol; 2020 Oct; 48():151576. PubMed ID: 32805517 [TBL] [Abstract][Full Text] [Related]
36. Impact of polysomy 17 on HER2 testing of invasive breast cancer patients. Liu Y; Ma L; Liu D; Yang Z; Yang C; Hu Z; Chen W; Yang Z; Chen S; Zhang Z Int J Clin Exp Pathol; 2014; 7(1):163-73. PubMed ID: 24427336 [TBL] [Abstract][Full Text] [Related]
37. Genetic alterations and protein expression of HER2 and chromosome 17 polysomy in breast cancer. Zhu X; Lu Y; Lu H; Yang W; Tu X; Cai X; Zhou X Hum Pathol; 2011 Oct; 42(10):1499-504. PubMed ID: 21676436 [TBL] [Abstract][Full Text] [Related]
38. Polysomy 17 in HER-2/neu status elaboration in breast cancer: effect on daily practice. Ma Y; Lespagnard L; Durbecq V; Paesmans M; Desmedt C; Gomez-Galdon M; Veys I; Cardoso F; Sotiriou C; Di Leo A; Piccart MJ; Larsimont D Clin Cancer Res; 2005 Jun; 11(12):4393-9. PubMed ID: 15958623 [TBL] [Abstract][Full Text] [Related]
39. [Clinicopathologic significance of chromosome 17 polysomy in breast cancer]. Lü YL; Zhong M; Liu L; Wei LX; Zhao P Zhonghua Bing Li Xue Za Zhi; 2008 Feb; 37(2):88-91. PubMed ID: 18681318 [TBL] [Abstract][Full Text] [Related]
40. Immunohistochemistry and alternative FISH testing in breast cancer with HER2 equivocal amplification. Agersborg S; Mixon C; Nguyen T; Aithal S; Sudarsanam S; Blocker F; Weiss L; Gasparini R; Jiang S; Chen W; Hess G; Albitar M Breast Cancer Res Treat; 2018 Jul; 170(2):321-328. PubMed ID: 29564742 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]